[{"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Ascletis Pharma"},{"company":"Shanghai Zhimeng Biopharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zhimeng Biopharma Announces the First-in-Human Dosing in Phase I Clinical Trial of ZM-H1505R ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Shanghai Zhimeng Biopharma"},{"company":"CanSino Biologics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cansino Biologics and Institute Of Biotechnology, Academy Of Military Medical Sciences Developing Novel Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"CanSino Biologics"},{"company":"I-Mab Biopharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release Syndrome in COVID-19\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"I-Mab Biopharma"},{"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First human trial of COVID-19 Vaccine from CanSino Biologic finds its Safe and Induces Rapid Immune Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"CanSino Biologics"},{"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves First Covid-19 Vaccine Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"CanSino Biologics"},{"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Doses First Healthy Volunteer in Phase I Clinical Study of SARS-CoV-2 Neutralizing Antibody JS016 in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Shanghai Junshi Biosciences"},{"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Biopharmaceuticals Initiates Phase 1 Clinical Trial for COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Clover Biopharmaceuticals"},{"company":"Clover Biopharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$66.0 million","newsHeadline":"CEPI to Invest $66 Million to Boost Clover's COVID-19 Vaccine Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Clover Biopharmaceuticals"},{"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of SARS-CoV-2 Neutralizing Antibody JS016 in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Shanghai Junshi Biosciences"},{"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Clover Biopharmaceuticals"},{"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Clover Applies for Philippines COVID-19 Vaccine Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Clover Biopharmaceuticals"},{"company":"Clover Biopharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$328.0 million","upfrontCash":"$69.5 million","newsHeadline":"CEPI Extends Partnership With Clover Biopharmaceuticals to Fund COVID-19 Vaccine Candidate Through Global Phase 2\/3 Study to Licensure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Clover Biopharmaceuticals"},{"company":"Jemincare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jemincare Initiates Phase I Clinical Trial of anti-SARS-CoV-2 Neutralizing Antibody JMB2002","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Jemincare"},{"company":"Jemincare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approved Jemincare to Initiate Clinical Trial of Neutralizing Antibody JMB2002","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Jemincare"},{"company":"GenEros BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenEros BioPharma\u2019s Clinflamozyde Approved for Clinical Trials for COVID-19 in the US","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"GenEros BioPharma"},{"company":"Prosit Sole Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prosit Sole Biotechnology Initiates First-In-Human Clinical Trial of Novel Interferon Lambda Chimera in US","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Prosit Sole Biotechnology"},{"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Received China IND Approval of Its FXR Agonist ASC42 for Chronic Hepatitis B Indication","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Ascletis Pharma"},{"company":"Jemincare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jemincare Group Has Completed the Phase I Clinical Trial of its anti-SARS-CoV-2 Neutralizing Antibody JMB2002","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Jemincare"},{"company":"Jiangsu Recbio Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recbio Receives Pharmaceutical Production License from Jiangsu Medical Products Administration for Production of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Jiangsu Recbio Technology"},{"company":"Jiangsu Recbio Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recbio Announces New Study Showing Its COVID-19 Vaccine Induced High Levels of Neutralizing Antibodies against SARS-CoV-2 and Variants of Concern","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Jiangsu Recbio Technology"},{"company":"Shanghai Zhimeng Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zhimeng Biopharma Announces Dosing of First Subject in First-in-Human Phase I Clinical Trial of CB06","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Shanghai Zhimeng Biopharma"},{"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D Day","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Jiangsu Simcere Pharmaceutical"},{"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIMCERE PHARMA (HK.2096) Novel Inhibitor of COVID-19 3CLpro SIM0417 Received a Second Clinical Trial Approval in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Jiangsu Simcere Pharmaceutical"},{"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Doses First Participants in Phase 1 Trial with SCB-2020S, a Potentially Broadly Protective Chimeric COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Clover Biopharmaceuticals"},{"company":"Shanghai Zhimeng Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zhimeng Biopharma Will Report Positive Phase 1b Trial Results on Its Hbv Capsid Inhibitor Zm-h1505r in the Upcoming International Liver Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Shanghai Zhimeng Biopharma"}]
Details:
ZM-H1505R is a small-molecule HBV capsid assembly modulator with a novel pyrazole structure currently being evaluated for the treatment of CHB. It is active against most HBV variants that show resistance to other HBV capsid modulators.
Lead Product(s):
ZM-H1505R
Therapeutic Area: Infections and Infectious Diseases
Product Name: ZM-H1505R
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 14, 2022
Details:
SCB-2020S is a second generation, potentially broadly protective COVID-19 vaccine candidate based on a chimeric Beta and prototype trimeric SARS-CoV-2 S-protein, preserving potential neutralization epitopes across multiple variants of concern of SARS-CoV-2, including Omicron.
Lead Product(s):
SCB-2020S,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases
Product Name: SCB-2020S
Highest Development Status: Phase I
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 31, 2022
Details:
SIM0417 has shown broad-spectrum antiviral activity, good in vivo pharmacokinetic properties, and safety in pre-clinical studies. It is a highly active, low toxicity, orally administrable small molecule anti-SARS-CoV-2 drug candidate.
Lead Product(s):
SIM0417
Therapeutic Area: Infections and Infectious Diseases
Product Name: SIM0417
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 17, 2022
Details:
First-in-class (FIC) novel myelo-protective drug trilaciclib targeting large Chinese patient population receiving chemotherapy, the product has the potential for delivering significant patient impact and commercial success.
Lead Product(s):
SIM0417
Therapeutic Area: Infections and Infectious Diseases
Product Name: SIM0417
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 15, 2022
Details:
CB06 is a small molecule, oral TLR8 agonist independently developed by Zhimeng, and it is the second candidate with exclusive intellectual property that successfully enters the clinical development stage, within Zhimeng’s innovative pipelines.
Lead Product(s):
CB06
Therapeutic Area: Infections and Infectious Diseases
Product Name: CB06
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 02, 2022
Details:
Recbio, together with Jiangsu Provincial Center for Disease Control and Prevention ("Jiangsu CDC") and Taizhou Medical New & High-tech Industrial Development Zone, jointly developed a recombinant two-component COVID-19 vaccine(ReCOV).
Lead Product(s):
ReCOV
Therapeutic Area: Infections and Infectious Diseases
Product Name: ReCOV
Highest Development Status: Phase I
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 16, 2021
Details:
This study used a variety of assays and showed that after two doses of ReCOV, high levels of neutralizing antibodies were generated against ancestral strain of the virus. The vaccinated sera also showed cross neutralizing activity against B.1.1.7, B.1.351, P.1 and B.1.617.2.
Lead Product(s):
ReCOV
Therapeutic Area: Infections and Infectious Diseases
Product Name: ReCOV
Highest Development Status: Phase I
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 08, 2021
Details:
The clinical trial of JMB2002 was a single-center, randomized, double-blind, placebo-controlled, single-dose escalation phase I trial was designed to evaluate JMB2002's tolerability, safety, pharmacokinetic characteristics and immunogenicity in healthy subjects.
Lead Product(s):
JMB2002
Therapeutic Area: Infections and Infectious Diseases
Product Name: JMB2002
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 13, 2021
Details:
ASC42 is an in-house developed, selective, potent farnesoid X receptor (FXR) agonist. ASC42 is an oral tablet formulation developed with in-house proprietary technology and is stable at room temperature.
Lead Product(s):
ASC42
Therapeutic Area: Infections and Infectious Diseases
Product Name: ASC42
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 07, 2021
Details:
PSP001 is a novel, long acting and potent interferon lambda chimera injection for the treatment of chronic norovirus enteritis in hematopoietic and solid organ transplant recipients.
Lead Product(s):
PSP001
Therapeutic Area: Infections and Infectious Diseases
Product Name: PSP001
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 26, 2021
Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
